British Liver Trust warns of fatty liver disease tsunami, due to the link between fatty liver disease and type 2 diabetes

June 13, 2024

Two-thirds of people living with type 2 diabetes also have fatty liver disease[i] – but they may not be aware of it, warns the British Liver Trust. Fatty liver disease also significantly heightens the risk of developing type 2 diabetes.   The charity urges people to get tested if they could be at risk, so both conditions can be managed effectively.

The National Institute for Health and Care Excellence (NICE) estimates that by 2025, more than 5 million people in the UK will be diagnosed with diabetes.  This means that the UK could be facing a tsunami of people newly diagnosed with fatty liver disease.

Fatty liver disease, or MASLD (metabolic dysfunction-associated steatotic liver disease), which is characterised by excess liver fat, presents a growing health concern.  Left unchecked, MASLD can escalate into severe MASH (metabolic associated steatohepatitis), potentially leading to liver failure or cancer.

Obesity is a major risk factor for both type 2 diabetes and fatty liver disease. By 2040, it is estimated that 21 million people in the UK will be obese.

Vanessa Hebditch, Director of Communications and Policy at the British Liver Trust, stresses the urgency: “If you are diagnosed with fatty liver disease, losing weight and eating a healthy diet is the first line of treatment. There is good evidence that losing 5 to 10% of body weight can control and, in some cases, reverse the condition.”

Fatty liver disease also significantly increases the risk of developing type 2 diabetes, a long-term condition that occurs when your body either doesn’t produce enough insulin, a hormone that regulates blood sugar, or the insulin produced doesn’t work properly.  A study by Diabetes UK in 2022 found that having higher levels of fat in the liver directly increases the risk of developing type 2 diabetes[i].

Vanessa continues, “Living with both fatty liver disease and type 2 diabetes can increase your likelihood of experiencing diabetes complications and developing more serious liver disease. For example, having both type 2 diabetes and fatty liver disease further increases your risk of heart disease[ii], so it’s important to find out if you could be affected.”

This call to action coincides with today’s (13th June 2024) Global Fatty Liver Day when organisations and people around the world unite to raise awareness of the urgent need for prevention, detection, and treatment of fatty liver disease.

Nine in 10 cases of liver disease are preventable with the main causes being excess weight, alcohol and viral hepatitis. To assess your risk of liver disease, visit www.britishlivertrust.org.uk/risk.

_________

References

[i] Ref Cho et al 2023 give prevalence of 65.04% and 31.55% for NAFLD and NASH respectively. 35.54 had clin sig fibrosis. Global MA and SR. https://pubmed.ncbi.nlm.nih.gov/37491159/

[i] https://www.diabetes.org.uk/about-us/news-and-views/liver-fat-risk-type-2-diabetes

[ii] Golabi et al 2023 Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States Metabolism 146: 155642 https://pubmed.ncbi.nlm.nih.gov/37380016/

More news

A new chapter for liver health: together we are Liver UK

A new chapter for liver health: together we are Liver UK

Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

The British Liver Trust welcomes the news that hundreds more liver transplants could be carried out after a new procedure that supplies a donor liver with oxygen before removal was approved by NICE for use in the NHS.   In-situ ...
New hope for people living with MASH as two treatments receive MHRA approval

New hope for people living with MASH as two treatments receive MHRA approval

People living with metabolic dysfunction-associated steatohepatitis (MASH) have received encouraging news, with the UK medicines regulator approving two treatments for the condition within the past month. The Medicines and Healthcare ...
No results found.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.